Do Parkinson’s disease patients disclose their adverse events spontaneously?

• Published in: European journal of clinical pharmacology Vol. 68; no. 5; pp. 857 - 865
• Main Authors: Perez-Lloret, Santiago, Rey, María Verónica, Fabre, Nelly, Ory, Fabienne, Spampinato, Umberto, Montastruc, Jean-Louis, Rascol, Olivier
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 01.05.2012; Springer; Springer Nature B.V
• Subjects: Age; Aged; Anticonvulsants. Antiepileptics. Antiparkinson agents; Antiparkinson Agents - adverse effects; Antiparkinson Agents - therapeutic use; Biological and medical sciences; Biomedical and Life Sciences; Biomedicine; Clinical trial. Drug monitoring; Cross-Sectional Studies; Data collections; Disclosure; Drug Monitoring; Drug therapy; Drug toxicity and drugs side effects treatment; Drugs; Epidemiology; Female; France; General pharmacology; Hospitals, University; Humans; Interviews as Topic; Inventories; Male; Medical sciences; Miscellaneous (drug allergy, mutagens, teratogens...); Movement disorders; Neurodegenerative diseases; Neuropharmacology; Outpatient Clinics, Hospital; Parkinson Disease - drug therapy; Parkinson's disease; Pharmacoepidemiology and Prescription; Pharmacology; Pharmacology. Drug treatments; Pharmacology/Toxicology; Sex; Side effects; Surveys and Questionnaires; France; Motor fluctuations; Underreporting; Pharmacological treatment; Dopamine agonists; Non-motor symptoms; Adverse drug reactions; Levodopa; Parkinson’s disease; Agonist; Parkinson's disease; Toxicity; Motor system disorder; Parkinson disease; Pharmacotherapy; Secondary effect; Degenerative disease; Neurological disorder; Human; Drug; Nervous system diseases; Fluctuations; Antiparkinson agent; Cerebral disorder; D2 Dopamine receptor; Treatment; Central nervous system disease; Dopamine agonist; Extrapyramidal syndrome

Background Underreporting of adverse drug reactions is common but has been rarely studied in Parkinson’s disease (PD). Objective To compare the prevalence of adverse events (AEs) in relation to antiparkinsonian drugs in PD patients using two different data collection methods: patient’s spontaneous r...